 |
|
|
|
|
|
|
|
|
|
MABTHERA (RA)
MABTHERA contains the active ingredient rituximab.
MABTHERA is used to treat non-Hodgkin's lymphoma (a type of blood cancer).
MABTHERA belongs to a group of medicines known as monoclonal antibodies. Monoclonal antibodies are proteins which specifically recognise and bind to another unique protein called an antigen.
MABTHERA works by binding to an antigen on the surface of certain white blood cells known as B lymphocytes. It is the abnormally growing B lymphocytes that are responsible for certain types of non-Hodgkin's lymphoma. During the process of binding to the antigen, the abnormal growth of the B lymphocytes is stopped.
MABTHERA may be used on its own or together with other chemotherapy.
Your doctor, however, may have prescribed MABTHERA for another purpose.
This medicine is available only with a doctor's prescription.
Back
|
|
|
|
|
|
|
|
|
|
